Tumor necrosis factor -related apoptosis -inducing ligand ( TRAIL / Apo2L ) has been shown to induce apoptosis in malignant cells without harming normal cells. To determine the antitumor potential of TRAIL against prostate cells, we undertook a comprehensive study that included eight prostate cancer cells lines ( CWR22Rv1, Du145, DuPro, JCA -1, LNCaP, PC -3, PPC -1, and TsuPr1 ) and primary cultures of normal prostate epithelial cells ( PrEC ). Cells were tested for susceptibility to soluble TRAIL in the presence or absence of the chemotherapeutic agent doxorubicin. TRAIL was also delivered by an adenoviral vector. Our results reveal that Du145, DuPro, LNCap, TsuPr1, and PrEC were resistant to 100 ng / mL TRAIL. JCA -1 and PPC -1 were slightly sensitive ( 20% killing ) and PC -3 and CWR22Rv1 exhibited the highest sensitivity to TRAIL ( 30% and 50% killing, respectively ). The combination of 10 ng / mL TRAIL with doxorubicin resulted in 60 -80% cytotoxicity in seven of eight prostate cancer cells. TRAIL -mediated apoptosis involved cleavage of Bid, caspase -3, and PARP, and required caspase -8 and -9 activity. Full -length TRAIL delivered by an adenoviral vector ( AdTRAIL -IRES -GFP ) killed prostate cancer cell lines and PrEC without requisite doxorubicin cotreatment. Therefore, expression of the transgene from a tissue -specific promotor would make gene therapy with AdTRAIL -IRES -GFP a possibility.
1
Treatment options are limited and are associated with significant morbidity and mortality. 2 If the cancer is localized, treatment options include radical prostatectomy, brachy -or cryotherapy, and external beam radiation. Cancer that has escaped the prostatic capsule is generally treated by hormone ablation, which on average prolongs survival by 18 months but is not curative, because tumors become hormone refractory. Chemotherapy is also generally ineffective because prostate tumors are slow growing. Curative therapies for advanced prostate cancer are currently not available and novel treatment approaches are explored in numerous clinical trials (www.clinicaltrials.gov ). Experimental approaches include delivery of oncolytic viruses, immunomodulatory molecules, p53 and p21, enzymes that metabolize prodrugs and agents that can induce apoptosis. 3 Tumor necrosis factor-related apoptosis -inducing ligand ( TRAIL /Apo -2L ) is a molecule that has received significant attention as a novel anticancer agent. 4 ,5 TRAIL induces receptor-mediated apoptosis similar to tumor necrosis factor and FasL but based on animal safety studies it appears to be less toxic. 6, 7 Last year concerns about TRAIL toxicity in humans emerged with reported adverse effects on primary cultures of human hepatocytes and brain tissue. 8, 9 It has now been shown that the different recombinant versions of TRAIL (Apo2L /TRAIL.0 and Apo2L /TRAIL.His ) used in the studies vary widely biochemically and in their potential for toxicity. Apo2L /TRAIL.0 did not induce apoptosis in human hepatocytes and failed to induce adverse effects in two primate models. 10 Therefore, Apo2L / TRAIL.0 is currently ''under preparation'' for a Phase I clinical trial ( www.genentech.com ).
In initial studies, TRAIL induced apoptosis in tumorigenic and transformed cells without adversely affecting normal cells. 4, 5, 11, 12 Recent studies, however, reveal that an increasing number of cancer cell lines and fresh tumor isolates are resistant to TRAIL -mediated apoptosis. 12 -15 The prostate cancer cell lines LNCaP and Du145 have been found to be relatively resistant to the apoptotic effects of 100 ng / mL TRAIL, 16 -18 suggesting that the use of soluble recombinant human TRAIL alone may be ineffective against prostate cancer. However, many chemotherapeutic agents can act synergistically with TRAIL to induce significant cell death, 19 indicating that combination therapy may be a possibility. One of the problems with in vivo use of TRAIL is the high concentration requirement, in part because soluble TRAIL has a short half -life in plasma and an elimination half -life of less than 5 hours. 7 To improve delivery, several laboratories including ours have developed adenoviral vectors that express TRAIL. 20, 21 The goal of this study was to determine the antitumor potential of TRAIL in prostate cancer cells. A few studies have examined the susceptibility of prostate cancer cells to TRAIL, sometimes with contradictory results. 22 Therefore, we undertook a comprehensive study that included eight prostate cancer cells lines and primary cultures of normal prostate epithelial cells (PrEC ). All cells were tested for susceptibility to cross -linked and non-cross -linked soluble TRAIL in the presence or absence of the chemotherapeutic agent doxorubicin. TRAIL was also delivered by an adenoviral vector. Our results confirm that externally applied, soluble TRAIL is not very efficient in inducing apoptosis of prostate cancer cells unless cells are cotreated with doxorubicin. Full -length TRAIL delivered by an adenoviral vector can overcome resistance to TRAIL without requisite cotreatment.
Methods

Cell lines and culture
The cell lines Du145 and PC -3 were purchased from the American Type Culture Collection ( Rockville, MD ). LNCaP cells were obtained from Urocor, Oklahoma City, OK. The other cell lines were kindly provided as follows: CWR22Rv1 from Dr. JW Jacobberger, Case Western Reserve ( Cleveland, OH ); DuPro from Dr. DF Jarrard, University of Wisconsin Comprehensive Cancer Center ( Madison, WI ); JCA -1 from Dr. Sensuke Konno, New York Medical College (New York, NY ); PPC -1 and TsuPr1 from Dr. Yi Liu, University of Tennessee (Memphis, TN ). All cell lines were maintained in RPMI 1640 medium (Gibco-BRL, Carlsbad, CA ) supplemented with heat -inactivated 10% fetal bovine serum ( Hyclone, Logan, UT ). Primary cultures of PrEC were purchased from Clonetics (San Diego, CA ) and were maintained as directed. All cells were cultured at 378C at an atmosphere of 5% CO 2 .
Construction of plasmids and recombinant adenoviral vectors
The cDNA of full -length TRAIL was generated by RT-PCR from RNA isolated from normal human lymphocytes, inserted into the TA cloning system (Invitrogen, Carlsbad, CA ) and verified by sequence analysis. TRAIL was subsequently cloned into the pIRES -EGFP vector ( Clontech, Palo Alto, CA ) to yield pTRAIL -IRES -GFP. This vector contains an encephalomyocarditis virus internal ribosome entry site ( IRES ) that allows the translation of two open-reading frames from one mRNA. Because TRAIL and enhanced green fluorescent protein (GFP ) are translated from the same mRNA, GFP served as a marker for cells expressing TRAIL.
Adenoviral vectors were constructed in the Adenoviral Core facility at our institution using ligation of pRAd containing the gene of interest and pLAd -C.rtTA into the adenovirus genome (sub 360). 23, 24 The adenoviral constructs expressing either GFP or TRAIL -IRES -GFP are replication -deficient derivatives of Ad5 in which transgene regulation can be achieved by adding tetracycline or its analog doxycycline. The CMV promoter and the rtTA element were cloned into the Ad5 E1A region. To minimize undesired expression of the transgene, the tetracycline regulated element (TRE )-transgene cassette was cloned into the right ITR. 24 Adenovirus was propagated in Figure 1 The cytotoxic effect of TRAIL on prostate cells. Cells were treated with 100 ng / mL soluble recombinant TRAIL for 24 hours and viability determined in the MTS assay. Results shown are the mean ± SEM from at least three independent experiments performed in triplicate. 
MTS viability assays
Cells were plated at concentrations of 1Â10 4 cells/well in 96 -well Primaria plates (Falcon, Bedford, MA ) and incubated overnight before treatment with 0 -100 ng/mL TRAIL. Non -cross -linked TRAIL ( TL -375) was obtained from R&D Systems ( Minneapolis, MN ) and cross -linked Killer-TRAIL 2 was purchased from Alexis (San Diego, CA ). Both preparations of TRAIL contain a polyhistidine tag. In combination studies, each cell line was treated with doxorubicin at a concentration of 0-1 g /mL (0 -1.84 M) in the absence or presence of TRAIL. For viral infections, cells were transduced with the indicated multiplicity of infection ( MOI ) in the presence of 5 g /mL doxycycline. In experiments with caspase inhibitors, cells were pretreated for 1 hour before adding TRAIL and /or doxorubicin or virus. IETD -fmk ( caspase -8 inhibitor ) and LEHD -fmk ( caspase-9 inhibitor) were purchased from Alexis, and ZVAD -fmk ( pan-caspase inhibitor ) was obtained from Biomol ( Plymouth Meeting, PA ). The final concentration of inhibitors in the assay was 25 -50 M, diluted from 10 mM stocks in DMSO. MTS [ 3-(4,5 -dimethylthiazol-2 -yl )-5-( 3-carboxymethoxyphenyl )-2 -( 4-sulfophenyl )-2H -tetrazolium ] assays ( Promega, Madison, WI ) were performed in triplicate at 24 hours posttreatment. Plates were read at an absorbance of 490 nm 2 hours after addition of MTS reagent using a Vmax kinetic microplate reader ( Molecular Devices, Sunnyvale, CA ). Background absorbance was subtracted using a control of media and MTS reagent to give the OD490. Percent cytotoxicity was calculated using the following formula: % cytotoxicity = 1À [ (OD of experimental /OD of control )Â100 ].
Flow cytometry analysis for the detection of GFP
JCA -1 cells were seeded at 7Â10 5 /60 -mm plate and following 18 -20 hours incubation cells were infected with either AdGFP or AdTRAIL -IRES -GFP in the presence of 50 M ZVAD -fmk. ZVAD -fmk was required to prevent AdTRAIL -IRES -GFP -induced cell death and loss of GFP fluorescence. 25 Twenty-four hours postinfection, cells were washed, trypsinized, and resuspended in PBS before flow cytometry ( FACSCalibur, Becton Dickinson, Bedford, MA ). A minimum of 10,000 events was scored for each sample.
Western blotting
JCA -1 cells were seeded at 7Â10
5 /60 -mm plate and following 18 -20 hours incubation, cells were treated with 100 ng /mL TRAIL or 1 g/mL doxorubicin or a combination of 10 ng /mL TRAIL and 1 g /mL doxorubicin. Alternatively, JCA -1 cells were infected with virus at an MOI of 100. Cells were rinsed with PBS (nonadherent cells collected by centrifugation ) and lysed in RIPA buffer ( 1% NP -40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS ] in PBS ) containing a mammalian protease inhibitor cocktail ( P-8340, Sigma, St. Louis, MO ). Lysates were stored at À 708C and were centrifuged ( 20,000Âg ) before performing protein assays on the supernatant (DC protein assay, Bio-Rad, Hercules, CA ). Twenty micrograms protein was separated on 4 -20% Tris -glycine Novex minigels and transferred to nitrocellulose for 3 hours at 300 mA. Membranes were blocked in 5% milk in TBSTween for at least 1 hour, and incubated with primary Figure 3 TRAIL -mediated killing in the presence of doxorubicin. Cells were incubated with 1 g / mL doxorubicin in the absence or presence of 10 ng / mL TRAIL for 24 hours. Data shown are the mean ± SEM from at least three independent experiments performed in triplicate. Doxorubicin data were derived from at least six independent experiments. The combination of doxorubicin and non -cross -linked TRAIL was not evaluated in PrEC.
Cancer Gene Therapy . Following three washes with TBSTween, membranes were incubated with HRP -conjugated anti -mouse ( 1:5,000, Sigma), anti -rabbit ( 1:50,000, Santa Cruz Biotechnology ), or anti -goat secondary antibody ( 1:50,000, Santa Cruz Biotechnology ). Blots were washed twice in TBS -Tween and once in TBS, followed by detection of the signal using the DuraWest Supersignal kit ( Pierce ).
Results
Prostate cancer cells are relatively resistant to soluble TRAIL
To determine the susceptibility of prostate cells to TRAILmediated killing, eight cancer cell lines and primary cultures of PrEC were incubated with 100 ng/ mL TRAIL for 24 hours and cytotoxicity measured in the MTS assay ( Fig 1) . In this colorimetric assay, the MTS tetrazolium compound is bioreduced in the mitochondria by cells that are metabolically active. Susceptibility was defined as a loss in OD490 by greater than 10%. Based on this definition, Du145, DuPro, LNCaP, TsuPr1, and PrEC were resistant to TRAIL and JCA -1 and PPC -1 cells were slightly susceptible ( about 20% cytotoxicity ). Higher concentrations of TRAIL (250 ng/ mL, cross -linked or 500 ng /mL non -cross -linked) did not increase the cytoxicity toward these cells (data not shown ). Among the selected panel of cell lines, CWR22Rv1 and PC -3 were the most susceptible, yet none of the prostate cancer cell lines tested were highly sensitive to soluble TRAIL. Killing with soluble TRAIL can be enhanced by cross -linking the ligand, presumably by facilitating cross -linking of ligand -receptor complexes and increasing the strength of the signal. Indeed, in PC -3 cells 50% cytotoxicity was obtained with either 100 ng /mL cross -linked TRAIL or a 5-fold higher concentration of non -cross -linked TRAIL ( data not shown). Six of the eight prostate lines were equally resistant to either form of TRAIL, with the exception of CWR22Rv1, which was sensitive only to cross -linked TRAIL.
Doxorubicin sensitizes cells to TRAIL -mediated killing
Because many chemotherapeutic agents have been shown to enhance TRAIL -mediated killing, we tested whether a similar effect could be achieved between the anthracycline doxorubicin and TRAIL. Doxorubicin was chosen because the drug is currently being evaluated in Phase III clinical trials in combination with corticosteroids or androgen ablation therapy for prostate cancer ( www.clinicaltrials.gov ). The dose of doxorubicin required to sensitize LNCaP cells to TRAIL was 1 g /mL or 1.84 M, a dose that is clinically achievable (Fig 2A ) . 26 Maximal cooperativity was obtained at 1 g /mL doxorubicin and 10 ng /mL TRAIL (Fig 2B ) . This dose of TRAIL did not have cytotoxic effects on any of Cancer Gene Therapy TRAIL -mediated apoptosis in prostate cancer C Voelkel -Johnson et al the cell lines when used alone. Doxorubicin alone had limited cytotoxicity in prostate cancer cell lines, but killed a significant percentage of PrEC ( Fig 3 ) . Combination of doxorubicin and TRAIL resulted in 60 -80% killing in seven of eight prostate cancer cell lines, with Du145 cells more resistant ( 40% ). Both forms of TRAIL killed the prostate cancer cells with similar efficiency, with the exception of CWR22Rv1, which required cross -linked TRAIL (Fig 3 ) . Because doxorubicin sensitized prostate cancer cells to TRAIL, our data indicate that the pathway of TRAILmediated cytotoxicity is intact in these cells.
TRAIL induces caspase -mediated apoptosis
TRAIL -mediated apoptosis has been shown to involve activation of the initiator caspase -8, which cleaves and activates several downstream substrates including caspase-3 and Bid. Cleavage of cytosolic Bid results in a 15 -kDa fragment (tBid ) that translocates to the mitochondria where it inserts into the membrane facilitating cytochrome c release. Following release of cytochrome c, it binds to apoptosis protease activation factor-1 and caspase -9 to form the apoptosome. Caspase -9 also activates the effector caspase -3. Effector caspases are responsible for cleaving vital substrates, including PARP. 27 To confirm that TRAIL -mediated killing was indeed apoptosis, we examined the status of caspase-3, Bid, and PARP in JCA -1 cells that have been treated with TRAIL, doxorubicin or a combination of both (Fig 4A ) . We found that the increase in PARP cleavage and decrease in the relative amounts of pro -caspase-3 and Bid corresponded to the amount of cell death observed in the MTS assay. Although loss of the 22-kDa form of Bid suggests proteolytic cleavage of the protein, the antibody did not recognize tBid. Therefore, to confirm involvement of the mitochondrial pathway we used a caspase-9 inhibitor. The irreversible caspase -9 inhibitor LEHD -fmk protected doxorubicin -treated JCA -1 cells from TRAIL -mediated killing when measured in the MTS assay (Fig 4B ) , as did the irreversible caspase -8 inhibitor IETD -fmk and the pancaspase inhibitor ZVAD -fmk. Similar results were obtained in CWR22Rv1, DuPro, PC -3, PPC -1, and TsuPr1 ( data not shown). Therefore, TRAIL mediates cell death by an apoptotic mechanism that involves caspase -8 and the mitochondrial pathway.
Expression of TRAIL from an adenoviral vector
One of the problems with in vivo use of soluble TRAIL is the high concentration requirement, due in part to its short halflife in plasma ( about 32 minutes ) and an elimination halflife of less than 5 hours. 7 Delivery of TRAIL via an adenoviral vector can potentially overcome this problem by Cancer Gene Therapy TRAIL -mediated apoptosis in prostate cancer C Voelkel -Johnson et al targeting TRAIL to the tumor site. In this study, we have used a replication -deficient adenoviral vector in which the gene of interest is placed under control of a tetracyclineinducible promotor (Fig 5 ) . Initially, to determine the efficacy of transgene regulation in the tet -On system, JCA -1 cells were infected with AdTRAIL -IRES -GFP or a control vector lacking TRAIL ( AdGFP ). GFP expression was detected by immunoblotting. In AdGFP infected cells, GFP was detected 8 hours postinfection, which was enhanced in the presence of doxycycline, a tetracycline analog utilized to induce transgene expression ( Fig 6A ) . Detection of GFP in the absence of doxycycline indicates that significant background expression occurs from the minimal CMV promotor utilized in the tet -On system. GFP expression from AdTRAIL -IRES -GFP was not detected until 12 hours in the presence of doxycycline. This discrepancy in GFP expression did not stem from differences in the number of cells infected ( Fig 6B ) but resulted from the amount of GFP expressed per cell (Fig 6C ) . The lower levels of GFP expressed from AdTRAIL -IRES -GFP are likely the result of less efficient translation from the IRES.
Protein isolated from JCA -1 cells infected with AdTRAIL -IRES -GFP was also examined for TRAIL expression by Western blotting (Fig 7A ) . The predicted size of TRAIL based on the cDNA is 32.5 kDa. 4 A band of the expected size appeared at 8 hours postinfection in the presence of doxycycline. TRAIL expression increased with time and was induced severalfold in the presence of doxycycline. Our antibody also detected a protein that migrated slightly slower than TRAIL. This band was detected in PrEC and all eight of the prostate cancer cell lines including PC -3 (data not shown), which have been shown to be negative for TRAIL expression with an antibody from a different source. 20 Therefore, we conclude this band to be nonspecific.
Infection with AdTRAIL overcomes TRAIL resistance in prostate cell lines
Protein isolated from adenovirus -infected JCA -1 cells was examined for PARP cleavage to determine whether AdTRAIL -IRES -GFP induced apoptosis. As shown in Figure 7B , infection with AdGFP did not result in any PARP cleavage. In contrast, in AdTRAIL -IRES -GFPinfected cells, PARP cleavage could be detected as early as 12 hours in the presence of doxycycline, indicating that PARP cleavage occurred approximately 4 hours after TRAIL expression. Increased PARP cleavage was observed at 24 hours postinfection; however, this was maximal with or without doxycycline treatment. Not surprisingly, doxycycline also failed to regulate cytotoxicity in the MTS assay ( data not shown). We conclude that the amount of TRAIL synthesized in the absence of doxycycline is sufficient to induce the apoptotic pathway.
The cytotoxic effect following infection with AdGFP and AdTRAIL -IRES -GFP was measured in all prostate cancer cell lines and PrEC at 24 hours using the MTS assay ( Fig 8 ) . AdGFP at an MOI of 100 did not result in cytotoxicity, except in CWR22Rv1, which are highly sensitive to viral infection. Higher doses of AdGFP caused up to 20% cell death (50% in CWR22Rv1). At an MOI of 100, infection with AdTRAIL-IRES -GFP resulted in 30 -60% cytotoxicity. At an MOI of 10, some TRAIL susceptibility was observed in the most sensitive cell lines, CWR22Rv1 and JCA -1, but at the 24-hour time point this lower dose had little effect on the viability of other prostate cells. PrEC were also killed when infected with AdTRAIL -IRES -GFP. Therefore, expression of TRAIL from our adenoviral vector does overcome resistance but is not selective for prostate cancer cells.
To confirm that AdTRAIL -IRES -GFP induces caspasemediated apoptosis, Du145 cells were treated with the pancaspase inhibitor ZVAD -fmk. ZVAD -fmk protected cells from AdTRAIL -IRES -GFP -mediated cytotoxicity (Fig 9 ) , indicating that AdTRAIL -IRES -GFP induced caspasedependent killing.
Discussion
This study was undertaken to evaluate the antineoplastic potential of TRAIL against prostate cancer. We confirmed, in agreement with several other investigations, that prostate cancer cells are relatively resistant to low levels of soluble TRAIL. 16 -18 Concentrations of TRAIL up to 4 g/mL can reduce the viability of Du145, PC -3, TsuPr1, and JCA -1 but not LNCaP cells. 18 However, we were unable to confirm a report that Du145 cells are sensitive to 100 ng /mL TRAIL, a difference that may be explained by clonal heterogeneity or the assay method used. 28 The observed TRAIL resistance of prostate cancer cells can be overcome by clinically achievable doses of doxorubicin ( 1 g /mL or 1.84 M). 26 However, this dose significantly affected the viability of primary cultures of PrEC ). Cyropreserved PrEC obtained from Clonetics are collected from a single donor, and we cannot rule out that the cells we used were unique with regard to doxorubicin susceptibility. In PrEC, combination of doxorubicin and TRAIL resulted in levels of cytotoxicity similar to those observed in prostate cancer cells. Although most of the toxicity was attributed to doxorubicin, two other studies using breast and mesothelial cells have demonstrated lack of selectivity for malignant cells when doxorubicin was combined with TRAIL. 13, 29 It is important to note that the recombinant TRAIL used in this study contains a histidinetag, which has been shown to have different biochemical and toxicological properties than TRAIL /Apo2L.0. 10 However, in the prostate cancer cell lines, we have tested noncross -linked TRAIL lacking a tag ( PeproTech ) with results comparable to those achieved with the histidine -tagged TRAIL purchased from R&D systems (Voelkel -Johnson, unpublished observations ).
A study using mono -and bivalent agonistic antibodies to DR4 and DR5 revealed that DR4 becomes activated by both the soluble and membrane -bound forms of the ligand whereas DR5 becomes activated only by membrane -bound TRAIL or TRAIL that has been cross -linked. 30 These observations suggest that TRAIL -induced apoptosis in CWR22Rv1 cells is mediated exclusively by DR5 whereas Figure 9 The effect of caspase inhibition on AdTRAIL -IRES -GFPmediated killing in Du145 cells. Cells were pretreated with ZVAD -fmk for 1 hour before adenoviral infection. Cytotoxicity was measured 24 hours postinfection. The results shown are from a single experiment performed in triplicate. 35 In contrast, lower concentrations of doxorubicin, which were sufficient to sensitize cells to TRAIL, did not result in elevation of TRAIL receptor expression 29, 36 or changes in receptor mRNA levels that correlated with sensitivity. 13 Therefore, changes in TRAIL receptor status following doxorubicin treatment may vary with the concentration or cell type studied. We are currently analyzing whether any changes in TRAIL receptors occur in prostate cancer cells following treatment with 1.84 M doxorubicin. Alternatively, doxorubicin may sensitize cells to TRAIL by affecting the intrinsic, mitochondrial pathway of apoptosis. 29 At least five of the prostate cancer cell lines we examined harbor p53 mutations ( Du145, JCA -1, PC -3, PPC -1, TsuPr1). 37 Only LNCaP and PrEC have confirmed wildtype p53. 37 Therefore, the synergistic effect observed between doxorubicin and TRAIL did not require functional p53. Du145, which was most refractory to the combined treatment, does not express the proapoptotic protein Bax. 16 It is possible that the lack of Bax contributes to resistance, because our data indicate the involvement of the mitochondrial pathway in TRAIL -mediated apoptosis.
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Resistance to soluble TRAIL is also overcome by expressing full -length TRAIL from an adenoviral vector. Viral proteins do not appear to play a role in sensitizing cells to TRAIL, because infection with AdGFP in combination with soluble TRAIL did not result in cytotoxicity (Voelkel -Johnson, unpublished observation ). Surprisingly, AdTRAIL -IRES -GFP caused cell death in PrEC. This result was unexpected because two other laboratories that developed TRAIL -expressing adenoviral vectors found normal cells ( PrEC and normal human lung fibroblasts ) to be resistant. 20, 21 The mechanism by which intracellular targeting of TRAIL overcomes resistance is currently under investigation in our laboratory.
Our study indicates that TRAIL has potential for the treatment of prostate cancer, which warrants further investigation. The combination of TRAIL with clinically achievable concentrations of doxorubicin resulted in cytotoxicity of all prostate cancer cells but also killed PrEC. Therefore it will be critical to evaluate combination treatment in other normal tissues. AdTRAIL -IRES -GFP was able to overcome resistance without requiring cotreatment with a chemotherapeutic agent. Again, this effect was not specific for malignant cells. However, expression of the transgene from a tissue -specific promotor such as probasin or PSA would make gene therapy with AdTRAIL -IRES -GFP a possibility.
